Business Context and Reporting Period
This Form 8-K filing by PharmAthene, Inc. (not Altimmune, Inc.) reports on the Annual Meeting of Stockholders held on June 10, 2015. The filing details the results of shareholder votes regarding director elections and other corporate proposals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Director Elections
Shareholders elected the following directors to serve until the next annual meeting. Significant broker non-votes were recorded for all candidates.
- John M. Gill: 21,454,525 votes for; 388,735 withheld.
- Eric I. Richman: 21,439,347 votes for; 403,913 withheld.
- Jeffrey W. Runge, M.D.: 21,458,525 votes for; 384,735 withheld.
- Mitchel B. Sayare, Ph.D.: 21,459,372 votes for; 383,888 withheld.
- Derace L. Schaffer, M.D.: 21,469,425 votes for; 373,835 withheld.
- Steven St. Peter, M.D.: 21,469,372 votes for; 373,888 withheld.
Other Proposals
- Executive Compensation (Say-on-Pay): Approved with 21,079,546 votes for, 636,066 against, and 127,648 abstentions.
- Ratification of Auditors: Ernst & Young LLP was ratified with 48,732,662 votes for, 1,192,953 against, and 111,517 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the company name is PharmAthene, Inc., as the input metadata incorrectly referenced Altimmune, Inc.
- Confirm the high volume of broker non-votes (28,193,872) for director elections and the Say-on-Pay proposal.
- Review the proxy statement for details on the executive compensation approved by shareholders.
- Check subsequent filings for financial performance data, as this 8-K contains no financial metrics.